trending Market Intelligence /marketintelligence/en/news-insights/trending/qh1cznohc8tznke1swweza2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Jaguar Health attracts private equity investment

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Jaguar Health attracts private equity investment

San Francisco's Jaguar Health Inc. agreed to issue 5,524,926 preferred shares in a private placement to Sagard Capital Partners LP, a private equity firm.

The company, which develops gastrointestinal therapies for humans and animals, expects to raise about $9.2 million through the placement.

Proceeds will go toward commercializing Jaguar Health's Mytesi, an anti-diarrheal drug for HIV/AIDS patients, and general corporate purposes.

Each preferred share is convertible into common shares of the company.

Sagard Capital Partners may also elect two directors to Jaguar Health's board under certain circumstances. To that end, Jaguar Health has already appointed Jeffrey Johnson to its board.

Johnson is a partner at Sagard Holdings ULC and an investment manager at Sagard Capital Partners Management Corp.

Concurrently, Jaguar Health issued $5 million worth of common shares at 17 cents each to certain institutional investors. The company said it will use proceeds to repay certain fees relating to its acquisition of Napo Pharmaceuticals Inc. in July 2017.